Eosinophil Dynamics May Help Differentiate Immune-Related From TKI-Related Adverse Events During IO-TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Background

Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO-TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune-related adverse events (irAEs) from TKI-related adverse events (TKI-AEs) is challenging because of overlapping clinical features. We aimed to evaluate whether eosinophil counts can help differentiate between them.